Neuropathic Ocular Pain Market, By Drug Class (Steroids, Non-Steroidal Anti-Inflammatory Drugs, Antidepressants, Anticonvulsants, Opioids, and Others (Vitamin B supplements, Botulinum toxin A, and others)), By Distribution Channel (Hospital Pharmacies, Re

Neuropathic Ocular Pain Market, By Drug Class (Steroids, Non-Steroidal Anti-Inflammatory Drugs, Antidepressants, Anticonvulsants, Opioids, and Others (Vitamin B supplements, Botulinum toxin A, and others)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), And by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Neuropathic pain is a pain condition that’s usually chronic. It’s usually caused by chronic, progressive nerve disease, and it can also occur as the result of injury or infection. Ocular neuropathic pain, also referred to as corneal neuropathic pain, is a condition where corneal pain is seen in response to normally non-painful stimuli. This results from repeated direct damage to corneal nerves. This damaged nerve sends pain signals to central nervous system (CNS) even in the absence of painful stimulus, thus, called “pain without stain” or “phantom cornea’. This condition is the ocular analog of systemic neuropathic pain, a complex regional pain syndrome, or reflex sympathetic dystrophy (RSD). Ocular or corneal neuropathic pain, corneal neuropathy, corneal neuralgia, kertaoneuralgia, and corneal allodynia are all terms that are used to describe the same disease entity.

Market Dynamics

An increase in government and non-government organizations' initiatives to improve access to affordable vision care and an increase in awareness among people regarding eye-related disease are expected to drive the market growth. Moreover, an increase in product launches by key market players is expected to drive the market growth over the forecast period. For instance, in November 2021, I-MED Pharma inc., a privately held Canada based eye care company, announced that it had launched an entire portfolio of dry eye products in the U.S. The products such as I-DROP, I-DEFENCE, and others, are intended to provide long-lasting relief from eye dryness, which is caused due to neuropathic ocular pain.

Key features of the study:

• This report provides an in-depth analysis of the global neuropathic ocular pain market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global neuropathic ocular pain market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include OKYO Pharma, Limited, Ocular Therapeutix, Inc., IACTA Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., Novartis AG, SALVAT, AbbVie Inc., Bausch & Lomb Incorporated, Kala Pharmaceuticals, Spectra Vision Care, Alcon Laboratories, AERIE PHARMACEUTICALS, INC., Optocred Pharmaceuticals and BRIM Biotechnology, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global neuropathic ocular pain market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neuropathic ocular pain market

Detailed Segmentation:

• Global Neuropathic Ocular Pain Market, By Drug Class:
• Steroids
• Non-Steroidal Anti-Inflammatory Drugs
• Antidepressants
• Anticonvulsants
• Opioids
• Others (Vitamin B supplements, Botulinum toxin A, and others)
• Global Neuropathic Ocular Pain Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Neuropathic Ocular Pain Market, By Region:
• North America
• By Country:
• U.S.
• Canada
• Latin America
• By Country:
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country:
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Country:
• GCC
• Israel
• Rest of Middle East
• Africa
• By Country/Region:
• South Africa
• Central Africa
• North Africa
• Company Profiles
• OKYO Pharma Limited*
• Company Highlights
• Products Portfolio
• Key Highlights
• Financial Performance
• Strategies
• Ocular Therapeutix, Inc.
• IACTA Pharmaceuticals, Inc.
• Sun Pharmaceutical Industries Ltd.
• Novartis AG
• SALVAT
• AbbVie Inc.
• Bausch & Lomb Incorporated
• Kala Pharmaceuticals
• Spectra Vision Care.
• Alcon Laboratories
• AERIE PHARMACEUTICALS, INC.
• Optocred Pharmaceuticals
• BRIM Biotechnology, Inc.

“*” marked represents similar segmentation in other categories in the respective section.